An important issue is whether these two discordant subsets – particularly those that are p16+/HPV- and therefore assigned as ‘HPV-positive’ by p16 routine testing – share the improved treatment response and survival outcomes of p16+/HPV+ cases, or whether outcomes are more closely aligned with p16-/HPV- tumours. This evidence concerns the gene CDKN2A and neoplasm.